NCT03331289View on ClinicalTrials.gov

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

PHASE4CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

March 31, 2022

Study Completion Date

November 4, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period

DRUG

Exenatide

Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period

DRUG

Dapagliflozin

Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period

DRUG

Exenatide and Dapagliflozin

Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period

Trial Locations (1)

78207

University Health System Texas Diabetic Institute, San Antonio

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT03331289 - Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria | Biotech Hunter | Biotech Hunter